Logo image of HURA

TUHURA BIOSCIENCES INC (HURA) Stock Fundamental Analysis

NASDAQ:HURA - Nasdaq - US8989201038 - Common Stock - Currency: USD

3.31  -0.41 (-11.02%)

After market: 3.54 +0.23 (+6.95%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to HURA. HURA was compared to 561 industry peers in the Biotechnology industry. HURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HURA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HURA has reported negative net income.
In the past year HURA has reported a negative cash flow from operations.
HURA had negative earnings in each of the past 5 years.
HURA had a negative operating cash flow in each of the past 5 years.
HURA Yearly Net Income VS EBIT VS OCF VS FCFHURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of HURA (-655.84%) is worse than 97.50% of its industry peers.
HURA has a Return On Equity of -1601.86%. This is amonst the worse of the industry: HURA underperforms 84.49% of its industry peers.
Industry RankSector Rank
ROA -655.84%
ROE -1601.86%
ROIC N/A
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A
HURA Yearly ROA, ROE, ROICHURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

HURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HURA Yearly Profit, Operating, Gross MarginsHURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for HURA has been reduced compared to 1 year ago.
The number of shares outstanding for HURA has been increased compared to 5 years ago.
HURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HURA Yearly Shares OutstandingHURA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
HURA Yearly Total Debt VS Total AssetsHURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -32.30, we must say that HURA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HURA (-32.30) is worse than 91.98% of its industry peers.
There is no outstanding debt for HURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.3
ROIC/WACCN/A
WACCN/A
HURA Yearly LT Debt VS Equity VS FCFHURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

HURA has a Current Ratio of 1.54. This is a normal value and indicates that HURA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.54, HURA is doing worse than 81.11% of the companies in the same industry.
A Quick Ratio of 1.54 indicates that HURA should not have too much problems paying its short term obligations.
HURA has a worse Quick ratio (1.54) than 80.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.54
HURA Yearly Current Assets VS Current LiabilitesHURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.32% over the past year.
EPS 1Y (TTM)5.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HURA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.44% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.7%
EPS Next 2Y-0.54%
EPS Next 3Y17.44%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HURA Yearly Revenue VS EstimatesHURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 20M 40M 60M
HURA Yearly EPS VS EstimatesHURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2K -4K -6K -8K -10K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HURA Price Earnings VS Forward Price EarningsHURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HURA Per share dataHURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

HURA's earnings are expected to grow with 17.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.54%
EPS Next 3Y17.44%

More info and screens

0

5. Dividend

5.1 Amount

HURA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TUHURA BIOSCIENCES INC

NASDAQ:HURA (5/21/2025, 5:41:07 PM)

After market: 3.54 +0.23 (+6.95%)

3.31

-0.41 (-11.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)10-06 2025-10-06/amc
Inst Owners5.11%
Inst Owner Change70.32%
Ins Owners33.29%
Ins Owner ChangeN/A
Market Cap144.58M
Analysts82.86
Price Target15.3 (362.24%)
Short Float %7.47%
Short Ratio9.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-52.55%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.81%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.13%
EPS NY rev (1m)11.27%
EPS NY rev (3m)26.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 85.3
P/tB 85.3
EV/EBITDA N/A
EPS(TTM)-5.32
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -655.84%
ROE -1601.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.54
Altman-Z -32.3
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)139.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.14%
EPS Next Y8.7%
EPS Next 2Y-0.54%
EPS Next 3Y17.44%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-136.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-176.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-211.84%
OCF growth 3YN/A
OCF growth 5YN/A